Supernus Pharmaceuticals Inc. (SUPN)
NASDAQ · Healthcare
Supernus Pharmaceuticals Inc. Income Statement 2010–2025
| Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenue | 719.0M | 661.8M | 607.5M | 667.2M | 579.8M | 520.4M | 392.8M | 408.9M | 302.2M | 215.0M | 147.5M | 92.7M | 12.0M | 1.5M | 803,000 | 106,000 |
| Gross Profit | 644.4M | 583.9M | 523.7M | 580.0M | — | 467.9M | 376.1M | 393.5M | 287.0M | 203.0M | 139.0M | 86.9M | 10.9M | — | — | — |
| Profitability | ||||||||||||||||
| Operating Income | -62.3M | 81.7M | -5.3M | 46.1M | 86.0M | 173.7M | 148.6M | 144.4M | 99.5M | 54.2M | 20.8M | -5.3M | -61.9M | -42.2M | -37.8M | -40.1M |
| EBITDA | 29.3M | 162.1M | 79.6M | 131.7M | 118.6M | 191.8M | 155.2M | 151.5M | 107.7M | 56.6M | 21.8M | -4.3M | -61.2M | -41.3M | -36.9M | -38.9M |
| Net Income | -38.5M | 73.9M | 1.3M | 60.7M | 53.4M | 127.0M | 113.1M | 111.0M | 57.3M | 91.2M | 13.9M | -10.9M | -92.3M | -46.3M | 53.8M | -38.5M |
| Per Share Data | ||||||||||||||||
| EPS (diluted) | $-0.68 | $1.32 | $0.02 | $1.04 | $0.98 | $2.36 | $2.10 | $2.05 | $1.08 | $1.76 | $0.28 | $-0.26 | $-2.90 | $-2.72 | — | — |
| Shares Outstanding (dil.) | 56M | 56M | 56M | 62M | 54M | 54M | 54M | 54M | 53M | 52M | 51M | 42M | 32M | 17M | 2M | 2M |
Supernus Pharmaceuticals Inc. Income Statement — FAQ
Supernus Pharmaceuticals Inc. (SUPN) income statement over the last 16 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see SUPN's income statement history?
The chart and table above show Supernus Pharmaceuticals Inc.'s income statement by year and by quarter, including the growth rate.